Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Cathomas

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Urologie (Heidelberg, Germany)|May 18, 2026
[Oligometastatic hormone-sensitive prostate cancer: when can less be more?]Richard Cathomas
European Journal of Cancer (Oxford, England : 1990)|November 4, 2020
Treading carefully in de-escalation for bone-targeted agents - is less more, after all?Anna Patrikidou, Richard Cathomas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Reply to V. Murthy et alRichard Cathomas, Jörg Beyer
European Urology|May 20, 2025
Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results from the Prospective BladderPath TrialChristian Daniel Fankhauser, Richard Cathomas
European Journal of Dermatology : EJD|February 14, 2009
"Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome"Roger Von Moos, Richard Cathomas
Oncology Research and Treatment|September 12, 2016
Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare DiseaseKatharina Mischler, Stefan Kneifel, Richard Cathomas
The Lancet. Oncology|February 1, 2023
Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? - Authors' replyAlexandros Papachristofilou, Stefanie Hayoz, Richard Cathomas
The New England Journal of Medicine|November 7, 2007
Drug-induced immune thrombocytopeniaRichard Cathomas, Aron Goldhirsch, Roger von Moos
The Lancet. Oncology|September 3, 2021
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancerCyrill A Rentsch, Stefanie Hayoz, Richard Cathomas
BMJ Case Reports|January 21, 2019
Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the linkMarius Vögelin, Richard Cathomas, Niklaus Kamber, et al.
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Urologie (Heidelberg, Germany)|May 18, 2026
[Oligometastatic hormone-sensitive prostate cancer: when can less be more?]Richard Cathomas
European Journal of Cancer (Oxford, England : 1990)|November 4, 2020
Treading carefully in de-escalation for bone-targeted agents - is less more, after all?Anna Patrikidou, Richard Cathomas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Reply to V. Murthy et alRichard Cathomas, Jörg Beyer
European Urology|May 20, 2025
Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results from the Prospective BladderPath TrialChristian Daniel Fankhauser, Richard Cathomas
European Journal of Dermatology : EJD|February 14, 2009
"Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome"Roger Von Moos, Richard Cathomas
Oncology Research and Treatment|September 12, 2016
Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare DiseaseKatharina Mischler, Stefan Kneifel, Richard Cathomas
The Lancet. Oncology|February 1, 2023
Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? - Authors' replyAlexandros Papachristofilou, Stefanie Hayoz, Richard Cathomas
The New England Journal of Medicine|November 7, 2007
Drug-induced immune thrombocytopeniaRichard Cathomas, Aron Goldhirsch, Roger von Moos
The Lancet. Oncology|September 3, 2021
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancerCyrill A Rentsch, Stefanie Hayoz, Richard Cathomas
BMJ Case Reports|January 21, 2019
Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the linkMarius Vögelin, Richard Cathomas, Niklaus Kamber, et al.
Pageof 14